EP3495352A1 — Crystal form of androgen receptor antagonist medication, preparation method therefor, and use
Assigned to Bayer Consumer Care AG · Expires 2019-06-12 · 7y expired
What this patent protects
The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (1)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has l…
USPTO Abstract
The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (1)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development.
Drugs covered by this patent
- Jesduvroq (DAPRODUSTAT) · GSK
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.